Pharmacological actions of statins: Potential utility in COPD

European Respiratory Review

Volumn 18, Issue 114, 2009, Pages 222-232

  Young, R P ^a   Hopkins, R ^a   Eaton, T E ^b  

^a UNIVERSITY OF AUCKLAND   (New Zealand)

^b AUCKLAND CITY HOSPITAL   (New Zealand)

Author keywords

Chronic obstructive pulmonary disease; Statins

Indexed keywords

BETA ADRENERGIC RECEPTOR STIMULATING AGENT; CORTICOSTEROID; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; PRAVASTATIN;

CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL ASSESSMENT; CLINICAL TRIAL; COMMUNITY ACQUIRED PNEUMONIA; DRUG EFFECT; DRUG INHIBITION; DRUG MECHANISM; HUMAN; NONHUMAN; OUTCOME ASSESSMENT; REVIEW;

HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE;

EID: 73449091199     PISSN: 09059180     EISSN: None     Source Type: Journal    
DOI: 10.1183/09059180.00005309     Document Type: Review

References (126)

1. Spurzem JR, Rennard SI. Pathogenesis of COPD. Semin Respir Crit Care Med 2005; 26: 142-153.
2. Altose MD. Approaches to slowing the progression of COPD. Curr Opin Pulm Med 2003; 9: 125-130.
3. Mannino DM, Watt G, Hole D, et al. The natural history of chronic obstructive pulmonary disease. Eur Respir J 2006; 27: 627-643.
4. Gan WQ, Man SFP, Senthilselvan A, et al. Association between chronic obstructive pulmonary disease and systemic inflammation: a systematic review and a meta-analysis. Thorax 2004; 59: 574-580.
5. Yende S, Waterer GW, Tolley EA, et al. Inflammatory markers are associated with ventilatory limitation and muscle dysfunction in obstructive lung disease in well functioning elderly subjects. Thorax 2006; 61: 10-16.
6. Sin DD, Man PSF. Why are patients with chronic obstructive pulmonary disease at increased risk of cardiovascular disease? The potential role of systemic inflammation in chronic obstructive pulmonary disease. Circulation 2003; 107: 1514-1519.
7. Barnes PJ, Celli BR. Systemic manifestations and comorbities in COPD. Eur Respir J 2009; 33: 1165-1185.
8. Rennard SI. Inflammation in COPD: a link to systemic comorbidities. Eur Respir Rev 2007; 16: 91-97.
9. Stockley RA. Neutrophils and the pathogenesis of COPD. Chest 2002; 121: Suppl. 5, 151S-155S.
10. Iho S, Tanaka Y, Takauji R, et al. Nicotine induces human neutrophils to produce IL-8 through the generation of peroxynitrite and subsequent activation of NF-kB. J Leukoc Biol 2003; 74: 942-951.
11. Abboud RT, Vimalanathan S. Pathogenesis of COPD. Part I. The role of protease-antiprotease imbalance in emphysema. Int J Tuberc Lung Dis 2008; 12: 361-367.
12. Roth M. Pathogenesis of COPD. Part III. Inflammation in COPD. Int J Tuberc Lung Dis 2008; 12: 375-380.
13. Langen RCJ, Korn SH, Wouters EFM. ROS in the local and systemic pathogenesis of COPD. Free Radic Biol Med 2003; 35: 226-35.
14. MacNee W, Rahman I. Is oxidative stress central to the pathogenesis of chronic obstructive pulmonary disease? Trends Mol Med 2001; 7: 55-62.
15. Tetley TD. Macrophages and the pathogenesis of COPD. Chest 2002; 121: Suppl. 5, 156S-159S.
16. Roman J, Ritzenthaler JD, Gil-Acosta A, et al. Nicotine and fibronectin expression in lung fibroblasts: implications for tobacco-related lung tissue remodeling. FASEB J 2004; 18: 1436-1438.
17. Carlisle DL, Hopkins TM, Gaither-Davis A, et al. Nicotine signals through muscle-type and neuronal nicotinic acetylcholine receptors in both human bronchial epithelial cells and airway fibroblasts. Respir Res 2004; 5: 1-16.
18. Demedts IK, Demoor T, Bracke KR, et al. Role of apoptosis in the pathogenesis of COPD and pulmonary emphysema. Respir Res 2006; 7: 53.
19. Brown V, Elborn JS, Bradley J, et al. Dysregulated apoptosis and NF-kB expression in COPD subjects. Respir Res 2009; 10: 24.
20. Kucharczak J, Simmons MJ, Fan Y, et al. To be, or not to be: NFkB is the answer - role of Rel/NF-kappaB in the regulation of apoptosis. Oncogene 2003; 22: 8961-8982.
21. Martinez FJ, MeiLan KH, Andrei AC, et al. Longitudinal change in the Bode index predicts mortality in severe emphysema. Am J Respir Crit Care Med 2008; 178: 491-499.
22. Hansen MJ, Gualano RC, Bozinovski S, et al. Therapeutic prospects to treat skeletal muscle wasting in COPD (chronic obstructive lung disease). Pharmacol Ther 2006; 109: 162-172.
23. Magio M, Guralnik JM, Longo DL, et al. Interleukin-6 in aging and chronic disease: a magnificent pathway. J Gerontol A Biol Sci Med Sci 2006; 61: 575-584.
24. Wilson DO, Weissfeld JL, Balkan A, et al. Association of radiographic emphysema and airflow obstruction with lung cancer. Am J Respir Crit Care Med 2008; 178: 738-744.
25. Young RP, Hopkins RJ, Christmas T, et al. COPD prevalence is increased in lung cancer, independent of age, sex and smoking history. Eur Respir J 2009; 34: 380-386.
26. de Torres J, Bastarrika G, Wisnivesky JP, et al. Assessing the relationship between lung cancer risk and emphysema detected on low dose CT of the chest. Chest 2007; 132: 1932-1938.
27. Mattson ME, Pollack ES, Cullen JW. What are the odds that smoking will kill you? Am J Pub Health 1987; 77: 425-431.
28. Young RP, Hopkins RJ, Hay BJ, et al. Lung cancer gene associated with COPD: triple whammy or possible confounding effect? Eur Respir J 2008; 32: 1158-1164.
29. Dasari V, Gallup M, Maltseva I, et al. Epithelial-mesenchymal transition in lung cancer: is tobacco the "smoking gun?". Am J Respir Cell Mol Biol 2006; 35: 3-9.
30. Shintani Y, Maeda M, Chaika N, et al. Collagen I promotes epithelial-to-mesenchymal transition in lung cancer cells via transforming growth factor- signaling. Am J Respir Cell Mol Biol 2008; 38: 95-104.
31. Kissil JL, Walmsley MJ, Hanlon L, et al. Requirement for Rac1 in a K-Ras-induced lung cancer in the Mouse. Cancer Res 2007; 67: 8089-8094.
32. Zondag GCM, Evers EE, ten Klooster JP, et al. Oncogene Ras down-regulates Rac activity, which leads to increased Rho activity in epithelial-mesenchymal transition. J Cell Biol 2000; 149: 775-782.
33. Barnes PJ, Karin M. Nuclear factor-kB: a pivotal transcription factor in chronic inflammatory diseases. N Eng J Med 1997; 336: 1066-1071.
34. Redline S, Tishler PV, Rosner B, et al. Genotypic and phenotypic similarities in pulmonary function among family members of adult monozygotic and dizygotic twins. Am J Epidemiol 1989; 129: 827-836.
35. Wilk JB, Djousse L, Arnett DK, et al. Evidence for major genes influencing pulmonary function in the NHLBI family heart study. Genet Epidemiol 2000; 19: 81-94.
36. Hoidal JR. Genetic of COPD: present and future. Eur Respir J 2001; 18: 741-743.
37. Weinshilboum R. Inheritance and drug response. N Eng J Med 2003; 348: 529-537.
38. Young RP, Hopkins RJ, Eaton TE. Forced expiratory volume in one second: not just a lung function test but a marker of premature death from all causes. Eur Respir J 2007; 30: 616-622.
39. Fletcher C, Peto R. The natural history of chronic airflow obstruction. BMJ 1977; 1: 1645-1648.
40. Lokke A, Lange P, Scharling H, et al. Developing COPD: a 25 year follow up study of the general population. Thorax 2006; 61: 935-939.
41. Stav D, Raz M. Prevalence of chronic obstructive pulmonary disease among smokers aged 45 and up in Israel. Isr Med Assoc J 2007; 9: 800-802.
42. Molfino NA. Genetics of COPD. Chest 2004; 125: 1929-1940.
43. Tockman MS, Comstock GW. Respiratory risk factors and mortality: longitudinal studies in Washington County, Maryland. Am Rev Respir Dis 1989; 140: S56-S63.
44. Olofson J, Skoogh BE, Bake B, et al. Mortality related to smoking habits, respiratory symptoms and lung function. Eur J Respir Dis 1987; 71: 69-76.
45. Yanbeva DG, Detener MA, Creutzberg EC, et al. Systemic inflammation in COPD: is genetic susceptibility a key factor. COPD 2006; 3: 51-61.
46. Hattotuwa KL, Gizycki MJ, Ansari TW, et al. The effects of inhaled fluticasone on airway inflammation in chronic obstructive pulmonary disease: a double-blind placebo-controlled biopsy study. Am J Respir Crit Care Med 2002; 165: 1592-1596.
47. Calverley PMA, Anderson JA, Celli B, et al. Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease. N Engl J Med 2007; 356: 775-789.
48. Lung Health Study Research Group. Effect of inhaled triamcinolone on the decline in pulmonary function in chronic obstructive pulmonary disease. N Eng J Med 200, 343: 1902-1909.
49. Sin DD, Man SFP. Skeletal muscle weakness, reduced exercise tolerance, and COPD: is systemic inflammation the missing link? Thorax 2006; 61: 1-3.
50. Roche N. Where current pharmacological therapies fall short in COPD: symptom control is not enough. Eur Respir Rev 2007; 16: 98-104.
51. Cazzola M, Ciaprini C, Page CP, et al. Targeting systemic inflammation: novel therapies for treatment of chronic obstructive pulmonary disease. Expert Opin Ther Targets 2007; 11: 1273-1286.
52. Hothersall E, McSharry C, Thomson NC. Potential therapeutic role for statins in respiratory disease. Thorax 2006; 61: 729-734.
53. Walsh GM. Statins as emerging treatments for asthma and chronic obstructive pulmonary disease. Expert Rev Respir Med 2008; 2: 329-335.
54. Pinto-Plata VM, Mullerova H, Toso JF, et al. C-reactive protein in patients with COPD, control smokers and non-smokers. Thorax 2006; 61: 23-28.
55. Gan WQ, Man SFP, Sin DD. The interactions between cigarette smoking and reduced lung function on systemic inflammation. Chest 2005; 127: 558-564.
56. Rasmussen F, Mikkelsen D, Hancox RJ, et al. High-sensitive C-reactive protein is associated with reduced lung function in adults. Eur Respir J 2009; 33: 382-388.
57. Walker RE, Wilk JB, Larsen MG, et al. Systemic inflammation and COPD: the Framingham Heart Study. Chest 2008; 133: 19-25.
58. Sin DD, Man SFP Interluekin 6, Chest 2008; 133: 4-6.
59. Kuhn C, Homer RJ, Zhu Z, et al. Airway responsiveness and airway obstruction in transgenic mice: morphologic correlates in mice overexpressing IL-11 and IL-6 in the lung. Am J Respir Cell Mol Biol 2000; 22: 289-295.
60. He J-Q, Foreman MG, Shumansky K, et al. Associations of IL-6 polymorphisms with lung function decline and COPD. Thorax 2009; 64: 698-704.
61. Amos CI, Wu X, Broderick P, et al. Genome-wide association scan of tag SNPs identifies a susceptibility locus for lung cancer at 15q25.1. Nat Genet 2008; 40: 616-622.
62. Young RP, Hopkins RJ, Bay BA, et al. Lung cancer susceptibility model based on age, family history and genetic variants. PLOS One 2009; 4: e5302.
63. Schonbeck U, Libby P. Inflammation, immunity, and HMG-CoA reductase: inhibitors: statins as anti-inflammatory agents? Circulation 2004; 109: I118-I126.
64. Melbye H, Halvorsen DS, Hartz I, et al. Bronchial airflow limitation, smoking, body mass index, and statin use are strongly associated with the C-reactive protein level in the elderly. The Tromsø Study 2001. Respir Med 2007; 101: 2541-2549.
65. Hurst JR, Hagan G, Wedzicha JA. Mechanism of statin-associated mortality reduction in COPD. Chest 2007; 132: 1409.
66. Young RP, Hopkins RJ, Eaton TE. Potential benefits of statins on morbidity and mortality in COPD: a review of the evidence. Postgrad Med J 2009; 85: 414-421.
67. Arnaud C, Burger F, Steffens S, et al. Statins reduce interleukin-6-induced c-reactive protein in human hepatocytes: new evidence for direct antiinflammatory effects of statins. Arterioscler Thromb Vasc Biol 2005; 25: 1231-1236.
68. Ikeda U, Shimada K. Statins and monocytes. Lancet 1999; 353: 2070.
69. Takayuki I, Ikeda U, Yamamoto K, et al. Regulation of interleukin-8 expression by HMG-CoA reductase inhibitors in human vascular smooth muscle cells. Atherosclerosis 2002; 165: 51-55.
70. Murphy DM, Forrest IA, Corris PA, et al. Simvastatin attenuates release of neutrophilic and remodeling factors from primary bronchial epithelial cells derived from stable lung transplant recipients. Am J Physiol Lung Cell Mol Physiol 2008; 294: L592-L599.
71. Xue-Mei O, Bai-ding W, Fu-qiang W, et al. Simvastatin attenuates lipopolysaccharide-induced airway mucus hyper-secretion in rats. Chin Med J 2008; 121: 1680-1687.
72. Ferro D, Parrotto S, Basili S, et al. Simvastatin inhibits the monocyte expression of proinflammatory cytokines in patients with hypercholesterolemia. J Am Coll Cardiol 2000; 36: 427-431.
73. Takahashi S, Nakamura H, Furuuchi M, et al. Simvastatin suppresses the development of elastase-induced emphysema in mice (abstract). Proc Am Thor Soc 2005; 2: A135.
74. Lee JH, Lee DS, Kim EK, et al. Simvastatin inhibits cigarette smoking-induced emphysema and pulmonary hypertension in rat lungs. Am J Respir Crit Care Med 2005; 172: 987-993.
75. Takahashi S, Nakamura H, Seki M, et al. Reversal of elastase-induced pulmonary emphysema and promotion of alveolar epithelial cell proliferation by simvastatin in mice. Am J Physiol Lung Cell Mol Physiol 2008; 294: L882-L890.
76. Maher BM, Ni Dhonnchu T, Burke JP, et al. Statins alter neutrophil migration by modulating cellular Rho activity - a potential mechanism for statins-mediated pleiotropic effects? J Leukoc Biol 2009; 85: 186-193.
77. Guasti L, Marino F, Cosentino M, et al. Simvastatin treatment modifies polymorphonuclear leukocyte function in high-risk individuals: a longitudinal study. J Hypertens 2006; 24: 2423-2430.
78. Kimura M, Kurose I, Russel J, et al. Effects of fluvastatin on leukocyte endothelial cell adhesion in hypercholesterolaemic mice. Arterioscler Thromb Vasc Biol 1997; 17: 1521-1526.
79. Scalia R, Gooszen ME, Jones SP, et al. Simvastatin exerts both anti-inflammatory and cardioprotective effects on apolipoprotein E-deficient mice. Circulation 2001; 103: 2598-2603.
80. Chello M, Patti G, Candura D, et al. Effects of atorvastatin on systemic inflammatory response after coronary bypass surgery. Crit Care Med 2006; 34: 660-667.
81. Montecucco F, Burger F, Pelli G, et al. Statins inhibit C-reactive protein-induced chemokine secretion, ICAM-1 up-regulation and chemotaxis in adherent human monocytes. Rheumatology 2009; 48: 233-242.
82. Nishibori M, Takahashi HK, Mori S. The regulation of ICAM-1 and LFA-1 interaction by autacoids and statins: a novel strategy for controlling inflammation and immune responses. J Pharmacol Sci 2003; 92: 7-12.
83. Jacobson JR, Barnard JW, Grigoryev DN, et al. Simvastatin attenuates vascular leak and inflammation in murine inflammatory lung injury. Am J Physiol Lung Cell Mol Physiol 2005; 288: L1026-L1032.
84. Frick M, Dulak J, Cisowski J, et al. Statins differentially regulate vascular endothelial growth factor synthesis in endothelial and vascular smooth muscle cells. Atherosclerosis 2003; 170: 229-236.
85. Morimoto K, Janssen WJ, Fessler MB, et al. Lovastatin enhances clearance of apoptotic cells (efferocytosis) with implications for chronic obstructive pulmonary disease. J Immunol 2006; 176: 7657-7665.
86. Newton CJ, Ran G, Xie YX, et al. Statin induced apoptosis of vascular endothelial cells is blocked by dexamethasone. J Endocrinol 2002; 174: 7-16.
87. Shishehbor MH, Brennan ML, Aviles RJ, et al. Statins promote potent systemic antioxidant effects through specific inflammatory pathways. Circulation 2003; 108: 426-431.
88. Rikitake Y, Kawashima S, Takeshita S, et al. Anti-oxidative properties of fluvastatin, an HMG-CoA reductase inhibitor, contribute to prevention of atherosclerosis in cholesterol-fed rabbits. Atherosclerosis 2001; 154: 87-96.
89. Mancini GBJ, Etminan M, Zhang B, et al. Reduction of morbidity and mortality by statins, angiotensin-converting enzyme inhibitors, and angiotensin receptor blockers in patients with chronic obstructive pulmonary disease. J Am Coll Cardiol 2006; 47: 2554-2560.
90. Keddissi JI, Younis WG, Chbeir EA, et al. The use of statins and lung function in current and former smokers. Chest 2007; 132: 1764-1771.
91. van Gestel YRBM, Hoeks SE, Sin DD, et al. Effect of statin therapy on mortality in patients with peripheral arterial disease and comparison of those with versus without associated chronic obstructive pulmonary disease. Am J Cardiol 2008; 102: 192-196.
92. Soyseth V, Brekke PH, Smith P, et al. Statin use is associated with reduced mortality in COPD. Eur Respir J 2007; 29: 279-283.
93. Frost FJ, Petersen H, Tollestrup K, et al. Influenza and COPD mortality protection as pleiotropic, dose-dependent effects of statins. Chest 2007; 131: 1006-1012.
94. Mortensen EM, Copeland LA, Pugh MJ, et al. Impact of statins and ACE inhibitors on mortality after COPD exacerbations. Respir Res 2009; 10: 45.
95. Blamoun AI, Batty GN, DeBari VA, et al. Statins may reduce episodes of exacerbation and the requirement for intubation in patients with COPD; evidence from a retrospective cohort study. Int J Clin Prac 2008; 62: 1373-1378.
96. Khurana V, Bejjanki HR, Caldito G, et al. Statins reduce the risk of lung cancer in humans: a large case-control study of US veterans. Chest 2007; 131: 1282-1288.
97. Farwell WR, Scranton RE, Lawler EV, et al. The association between statins and cancer incidence in a veterans population. J Natl Cancer Inst 2008; 100: 134-139.
98. Karp I, Behlouli H, LeLorier J, et al. Statins and cancer. Am J Med 2008; 121: 302-309.
99. Janda S, Park K, Fitzgerald JM, et al. Statins in COPD: a systemic review. Chest 2009; 136: 734-743.
100. Dobler CC, Wong KK, Marks GB. Association between statins and COPD: a systematic review. BMC Pulm Med 2009; 9: 32.
101. Alexeeff SE, Litonjua AA, Sparrow D, et al. Statin use reduces decline in lung function: VA Normative Aging Study. Am J Respir Crit Care Med 2007; 176: 742-747.
102. Mortensen EM, Restrepo MI, Anzueto A, et al. The effect of prior statin use on 30-day mortality for patients hospitalised with community acquired pneumonia. Respir Res 2005; 6: 82.
103. Majumdar SR, McAlister FA, Eurich DT, et al. Statins and outcomes in patients admitted to hospital with community acquired pneumonia: population based prospective cohort study. BMJ 2006; 333: 999.
104. Schlienger RG, Fedson DS, Jick SS, et al. Statins and the risk of pneumonia: a population based nested case control study. Phrmacotherapy 2007; 27: 325-332.
105. Charmers JD, Singanayagam A, Murray MP, et al. Prior statin use is associated with improved outcomes in community acquired pneumonia. Am J Med 2008; 121: 1002-1007.
106. Thomsen RW, Rus A, Kormun JB, et al. Preadmission use of statins and outcomes after hospitalisation with pneumonia: population based cohort study of 29900 patients. Arch Intern Med 2008; 168: 2081-2087.
107. Mortensen EM, PughMJ, Copeland LA, et al. Impact of statins and angiotensin-converting enzyme inhibitors on mortality of subjects hospitalised with pneumonia. Eur Respir J 2008; 31: 611-617.
108. Dublin S, Jackson ML, Nelson JC, et al. Statin use and risk of community acquired pneumonia in older people: population based case-control study. BMJ 2009; 338: b2137.
109. Myles PR, Hubbard RB, Gibson JE, et al. The impact of statins, ACE inhibitors and gastric acid suppresants on pneumonia moertaility in a UK general practice population cohort. Pharmacoepidemiol Drug Saf 2009; 18: 697-703.
110. Heart Protection Study collaborative Group. The effects of cholesterol lowering with simvastatin on cause-specific mortality and on cancer incidence in 20,536 high-risk people: a randomized placebo-controlled trial [ISRCTN48489393]. BMC Med 2005; 3: 6.
111. Lee T-M, Lin M-S, Chang N-C. Usefulness of C-reactive protein and interleukin-6 as predictors of outcomes in patients with chronic obstructive pulmonary disease receiving pravastatin. Am J Cardiol 2008; 101: 530-535.
112. Nohria A, Prsic A, Liu P-Y, et al. Statins inhibit Rho kinase activity in patients with atherosclerosis. Atherosclerosis 2009; 205: 517-521.
113. Ridker PM, Danielson E, Fonseca FAH, et al. Rosuvastatin to prevent vascular events in men and women with elevated Creactive protein. N Eng J Med 2008; 359: 2195-2207.
114. Weitz-Schmidt G, Welzenbach K, Brinkmann V, et al. Statins selectively inhibit leukocyte function antigen-1 by binding to a novel regulatory integrin site. Nature Med 2001; 7: 687-692.
115. Takahashi HK, Mori S, Iwagaki H, et al. Differential effect of LFA703, proavastatin, and fluvastatin on production of IL-18 and expression of ICAM-1 and CD40 in human monocytes. J Leukoc Biol 2005; 77: 400-407.
116. Wei CY, Huang KC, Chou YH, et al. The role of Rho-associated kinase in differential regulation by statins of IL-1B and LPSmediated NFkB activation and iNOS gene expression in vascular smooth muscle cells. Mol Pharmacol 2006; 69: 960-967.
117. Liao JK. Clinical implications for statin pleiotropy. Curr Opin Lipidol 2005; 16: 624-629.
118. Iwata A, Shirai R, Umeki K, et al. Anti-inflammatory effect of statins on human bronchial epithelial cells. American Thoracic Society, San Diego 2009. A3735.
119. Girgis RF, Mozammel S, Champion HC, et al. Regression of chronic hypoxic pulmonary hypertension by simvastatin. Am J Physiol Lung Cell Mol Physiol 2007; 292: L1105-L1110.
120. Hsu HH, Ko WJ, Hsu JY, et al. Simvastatin ameliorates established pulmonary hypertension through a hemeoxygenase-1 dependent pathway in rats. Respir Res 2009; 10: 32.
121. Johnson BA, Iacono AT, Zeevi A, et al. Statin use is associated with improved function and survival of lung allografts. Am J Respir Crit Care Med 2003; 167: 1271-1278.
122. Bellosta S, Via D, Canavesi P, et al. HMGCoA reductase inhibitors reduce MMP-9 secretion by macrophages. Arterioscler Thromb Vasc Biol 1998; 18: 1671-1678.
123. Ikeda U, Shimpo M, Ohki R, et al. Fluvastatin inhibits matrix metalloproteinase-1 expression in human vascular endothelial cells. Hypertension 2000; 36: 325-329.
124. Black M. Atherosclerosis, COPD and chronic inflammation. Respir Med 2008: 4; 60-65.
125. Mehra MR, Raval NY. Meta-analysis of statins and survival in de novo cardiac transplantation. Transplant Proc 2004; 36: 1539-1541.
126. Cazzola M. From large clinical trials to management of COPD in the real world. Ther Adv Respir Dis 2009; 3: 39-46.